Acknowledgement to the Reviewers
Kiyoshi Ito(Japan Cancer Society), Sandro Barni, Kenji Sugio(University of Occupational and Environmental Health Japan), E. Chamorey, C. Balu-Maestro, Masafumi Toyoshima(Nippon Medical School Hospital), M. Lallement, Makoto Kammori(Noguchi Thyroid Clinic and Hospital Foundation), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Stefano Cascinu(Vita-Salute San Raffaele University), Kosuke Yoshinaga, Hideki Tokunaga(Tohoku University), F. Ettore, Sahdeo Prasad(The University of Texas MD Anderson Cancer Center), Fulan Wei(Shandong University), Kosei Yasumoto(Japan Cancer Society), Yuhua Zhang(State Key Laboratory of Digital Medical Engineering), Satoru Nagase(Yamagata University), Tadao Takano(Tohoku University), Mistuhiro Takenoyama, Jun‐ichi Akahira, Neetu Kalra(Azim Premji University), Junko Aida(Tokyo Metropolitan Institute of Gerontology), Michio Kaminishi(Showa General Hospital), I. Raoust, Isabelle Peyrottes, C. Chapellier, Rie Kurabayashi, Hitoshi Niikura(Tohoku University), Luigi Dogliotti(Aarhus University Hospital), Takeshi Hanagiri, Xiaofang Zhang, Kenichi Nakamura(Japan Clinical Cancer Research Organization), Yongping Cai(Michigan State University), M. P. Singh, Yuichi Wada, Deling Yin(Second Affiliated Hospital of Zhejiang University), Gengyin Zhou, Huaiping Wang, Uma Singh, R. Largillier, Tsunehiro Oyama, Tadahiro Nozoe, Yogeshwer Shukla(Indian Institute of Toxicology Research), Naotaka Izumiyama, Toru Tase(Miyagi Prefectural Hospital Organization), Steven S.S. Poon(Leiden University), A. Courdi, J-M Ferrero(Centre Antoine Lacassagne), Mitsuhiko Kashio
Cited by 0
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
|Journal of Clinical Oncology|2005|1.9k
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k